曾因药物天价涨价事件备受争议的Martin Shkreli在出狱后重新进入公众视野。[1]Shkreli于2022年获释，此前因误导投资者欺诈罪被判刑4年多。[1]他因在2015年将Daraprim药物价格从13.50美元暴涨至750美元而臭名昭著，[1]并被判赔偿近6500万美元。[1]
自2024年11月起，Shkreli在YouTube上几乎每日直播，通常持续数小时。[1]他通过YouTube、社交媒体平台X、Substack和Discord等渠道发布股票分析和做空观点。[1]其YouTube频道已吸引超过93000名粉丝，X平台粉丝超过50万。[1]Shkreli利用允许金融出版物发布非个人投资建议无需注册的法律漏洞进行活动。[1]
Shkreli的做空预测记录并不理想。[1]在12个做空公告中，8个股票在公布当天下跌9%-45%，但一年内平均涨幅约40%。[1]他的看空目标包括SpaceX、英特尔和Moderna等科技巨头。[1]其中，Capricor股票在其做空公告后19天内反弹至原价的4倍多，累计上涨超过300%。[1]
尽管Shkreli重新活跃，他因欺诈获刑后被终身禁止从事制药行业，并被禁止某些证券工作。[1]
Martin Shkreli, the pharmaceutical executive infamous for raising the price of the drug Daraprim from $13.50 to $750 per pill in 2015, has reemerged in the public sphere following his release from prison in 2022 [1]. After serving more than four years for defrauding investors, Shkreli was ordered to pay restitution of nearly $65 million and was permanently barred from working in the pharmaceutical industry [1]. Now, he is attempting to reclaim attention through financial commentary and stock market predictions distributed across multiple online platforms.
Since November 2024, Shkreli has been broadcasting almost daily on YouTube, typically streaming for several hours at a time [1]. His online presence has grown substantially, with his YouTube channel attracting over 93,000 subscribers and his X account reaching more than 500,000 followers [1]. Beyond these platforms, he maintains a Discord channel and uses Substack to share stock analysis and short-selling recommendations [1]. Shkreli's strategy exploits a legal exemption that permits financial publications to distribute non-personalized investment advice without registering with regulators [1].
The impact of his market commentary has been significant, with stocks he has targeted experiencing price movements exceeding 40 percent [1]. However, his track record as an analyst has proven inconsistent. Among twelve short-selling recommendations he has made public, eight stocks fell between 9 and 45 percent on the day of announcement [1]. Yet overall, the group of targeted stocks averaged approximately 40 percent gains [1]. Most strikingly, Capricor stock rallied to more than four times its price within nineteen days of his short recommendation, accumulating gains exceeding 300 percent [1]. His short-selling targets have included major technology companies such as SpaceX, Intel, and Moderna [1].